Zhejiang Hisun Pharmaceutical Co (SHSE:600267) YoY EBITDA Growth : -9.33% (As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is Zhejiang Hisun Pharmaceutical Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Zhejiang Hisun Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -9.33%.

Zhejiang Hisun Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2025 was ¥0.24.

Zhejiang Hisun Pharmaceutical Co YoY EBITDA Growth Historical Data

The historical data trend for Zhejiang Hisun Pharmaceutical Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Hisun Pharmaceutical Co YoY EBITDA Growth Chart

Zhejiang Hisun Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

10.00

-24.35

0.52

-41.24

67.52

Zhejiang Hisun Pharmaceutical Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															3.88	2.34	21.82	125.59	-9.33

Zhejiang Hisun Pharmaceutical Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Zhejiang Hisun Pharmaceutical Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(1.697	-	1.013)	/	\| 1.013 \|
=	67.52 %

Zhejiang Hisun Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(0.243	-	0.268)	/	\| 0.268 \|
=	-9.33 %

Zhejiang Hisun Pharmaceutical Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Zhejiang Hisun Pharmaceutical Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Hisun Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Hisun Pharmaceutical Co Ltd (SHSE:600267) » Definitions » YoY EBITDA Growth

Traded in Other Exchanges

N/A

Address

No. 46 Waisha Road, Jiaojiang District, Zhejiang Province, Taizhou, CHN, 318000

Website

http://www.hisunpharm.com

Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.

Executives

Yu Shun Bing	Supervisors
Jin Hong Shun	senior management
Lu Xing Hai	senior management
Zhang Zhen Ying	senior management
Jiang Guo Ping	Director
Yang Zhi Qing	senior management
Du Jia Qiu	senior management
Chen Xiao Hua	Directors, senior managers
Li Yan	Directors, senior managers
Zhao Lei	senior management
Shen Xi Fei	Director
Zhang Wei	senior management
Bai Hua	Director
Chen Li Fei	Supervisors
Hu Liang Bin	senior management

Zhejiang Hisun Pharmaceutical Co Headlines

No Headlines